Gastroesophageal Reflux Disease (GERD)
- Home
- Solutions
- By Diseases
- Esophageal Diseases
- Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease (GERD) is explained as troublesome reflux or erosive changes in the esophagus that occur due to retrograde reflux of gastric contents. Protheragen is a research service provider focusing on preclinical drug development for GERD, developing customized solutions based on the requirements of our clients and development projects.
Gastroesophageal reflux disease (GERD) is a medical condition that arises due to the retrograde flow of refluxate into the esophagus. The disorder is complex itself as many syndromes are attributed to it and which are worsened due to the gastroesophageal reflux which leads to embodiments that are manifold and primary regarding terrible symptoms. There is a very high prevalence of GERD in every part of the globe and its epidemiology correlates to the lifestyle, obesity, and the demise of Helicobacter pylori.
Fig.1 Impact of different reflux components on the esophageal mucosa. (Sharma, P., and Yadlapati, R., 2021)In a typical situation, there has always existed an equilibrium between the protective anti-reflux action of the esophagus and the destructive effects of the refluxate upon the esophageal mucosa. The equilibrium is disrupted, and GERD is prone to occur if either the defense mechanisms of the former have been disabled, or the damaging effect of the latter has been strengthened. The most important primary pathophysiological processes that underlie GERD are the weakening of the anti-reflux barrier as well as the impairment of the esophageal clearance mechanism.
Fig.2 The complex pathogenesis of GERD. (Chhabra, P., and Ingole, N., 2022)| Drug Names | Mechanism of Action | Targets | Research Phase |
| Omeprazole | Inhibiting the acid production of stomach parietal cells, thereby diminishing the acid's capacity to irritate the esophagus. | Proton pump | Approved |
| IW 3718 | Preventing bile from reaching the esophagus post-binding, effectively blocking its entry. | FABP6 | Phase III |
| Alginates | Eliminating both pepsin and various bile acids. | Pepsin | Approved |
| Baclofen | Maintaining adequate LES tonicity and reducing the occurrence of TLESRs. | GABAB receptor | Approved |
| XP oral solution | Averting prolonged contact between acid reflux and the esophageal mucosa. | / | Preclinical |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Employing the latest technologies and methods to guarantee top-notch standards in preclinical research given our vast experience in preclinical drug development of GERD. Our services span from the development of diagnostic and therapeutic to the creation of disease models resulting in complete services for your specific field's requirements.
Induced Disease Model Development: A non-surgical animal model is developed where GERD from overeating is induced in mice. Mice are induced to overeat by control diets that involve cyclic fasting and feeding.
Surgical Model Development: Various methods, such as pyloric ligation, esophagojejunostomy, and esophagogastric anastomosis, can be performed on animals to create GERD.
Moreover, Protheragen also offers services such as evaluation of drug safety and pharmacokinetics to evaluate if the established drug candidates are in the safe range, which is useful in the refinement of therapeutic plans. We invite you to partner with us and obtain drug development tactics for GERD during the preclinical stages and let us assist you with the evolution of your therapeutic development projects. Contact us to discuss the details of our services and how we can meet your research objectives together.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.